 |
12 Diseases |  |
2 Trials |
|
2 Trials |  |
6 News |  |
- | MB07133 / Xi'an XinTong Pharma
New P2 trial: MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 21, 2023
P2, N=91, Recruiting, Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- | MB07133 / Xi'an XinTong Pharma
New P1/2 trial: Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 20, 2023
P1/2, N=39, Recruiting, Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- MB07133 / Ligand
SAFETY,TOLERABILITY AND EFFICACY OF MB07133, A LIVER-TARGETED PRODRUG OF ARACMP, IN PATIENTS WITH PRIMARY LIVER CANCER (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1075;
They all demonstrated that MB07133 is well tolerable and effective in patients with primary liver cancer, especially digestive side effects are milder.It might be an additional treatment option for primary liver cancer patients. The product is undergoing further assessment in the forthcoming phase II/III trials.
- | MB07133 / Xi'an XinTong Pharma
Trial completion: Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=28, Completed, Sponsor: Ligand Pharmaceuticals
The product is undergoing further assessment in the forthcoming phase II/III trials. No longer recruiting --> Completed
- | MB07133 / Xi'an XinTong Pharma
Enrollment change: Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 10, 2011
P1/2, N=28, Completed, Sponsor: Ligand Pharmaceuticals
No longer recruiting --> Completed N=36 --> 28